Serum transaminase elevations during pegylated interferon treatment of chronic HCV hepatitis probably induced by polyethylene glycol

Intervirology

Volumn 51, Issue 6, 2009, Pages 407-409

  Caroleo, B ^a   Gallelli, L ^a   Staltari, O ^a   De Sarro, G ^a   Guadagnino, V ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Alanine aminotransferase; Hepatitis C virus patient; Pegylated interferon alpha 2a; Pegylated interferon alpha 2b

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS C VACCINE; MACROGOL; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD ANALYSIS; CASE REPORT; CONCENTRATION (PARAMETERS); DRUG WITHDRAWAL; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; MALE; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROPHYLAXIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA VIRUS; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VACCINATION;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER; MALE; POLYETHYLENE GLYCOLS; RIBAVIRIN;

HEPATITIS C VIRUS;

EID: 61349198232     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000205266     Document Type: Article

References (10)

1. Thurairajah PH, Thorburn D, Hubscher S, White A, Lai WK, O'Donnell K, Mutimer D: Incidence and characterization of serum transaminases elevations in pegylated interferon and ribavirin treated patients with chronic hepatitis C. Aliment Pharmacol Ther 2007; 25: 1293-1300.
2. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.
3. Guitton E, Barange K, Bagheri H, Montastruc JL, Vinel JP, Claeyssens S, Bonnet E, Massip P: Blood transaminase elevation with pegylated interferon alfa 2b plus ribavirin in an HIV/HCV coinfected haemophilic patient. Infection 2006; 34: 183-185.
4. Nagashima M, Kudo M, Chung H, Ishikawa E, Inoue T, Nakatani T, Dote K: Elevated serum ALT levels during pegylated interferon monotherapy may be caused by hepatic iron overload. Intervirology 2008; 51(suppl 1):76- 85.
5. Peginterferon alfa-2a prescribing information. Roche Laboratories, Nutley, N.J.
6. Vogel W: Peginterferon-alpha 2a (40 kDa)/ ribavirin combination for the treatment of chronic hepatitis C infection. Expert Rev Anti Infect The 2003; 1: 423-431.
7. Manns MP, McHutchison JG, Gordon SC, et al: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
8. Fried MW, Shiffman ML, Reddy KR, et al: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
9. Poynard T, Marcellin P, Lee SS, et al: Randomised trial of interferon- 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon- 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.
10. McHutchison JG, Gordon SC, Schiff ER, et al: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.